Economic analysis of influenza vaccination and antiviral treatment for healthy working adults

Annals of Internal Medicine

Volumn 137, Issue 4, 2002, Pages 225-231

  Lee, Patrick Y ^a   Matchar, David B ^a   Clements, Dennis A ^a   Huber, Joel ^a   Hamilton, John D ^a   Peterson, Eric D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ABSENTEEISM; ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION THEORY; EMPLOYEE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; SYMPTOM; VERTIGO;

EID: 0037143533     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-4-200208200-00005     Document Type: Article

References (36)

1. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985
2. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
3. Vaccines for preventing influenza in healthy adults
4. How a new policy led to seven deadly drugs
5. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial
6. Advances in influenza virus vaccine research
7. Estimates of the US health impact of influenza
8. The effectiveness of vaccination against influenza in healthy, working adults
9. Effective protection against influenza after vaccination with subunit vaccine
10. Amantadine and rimantadine for preventing and treating influenza A in adults
11. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
12. Neuraminidase inhibitors for preventing and treating influenza in healthy adults
13. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults
14. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza
15. Antiviral agents for treating influenza
16. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population
17. Economic impact of influenza. The individual's perspective
18. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections
19. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
20. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
21. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
22. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
23. Influenza virus neuraminidase inhibitors
24. Medical decision-making and the patient: Understanding preference patterns for growth hormone therapy using conjoint analysis
25. Influenza vaccine for healthy working adults
26. Prevention and early treatment of influenza in healthy adults
27. Implications of viral resistance to amantadine in control of influenza A
28. Resistance of influenza A virus to amantadine and rimantadine: Results of one decade of surveillance